Aescap Life Sciences Quarterly Update Q3 2021

The overall risk awareness in the stock market has driven the average share prices of biotech companies down 5% in Q3. The fund’s net performance for Q3 was -5,7%. As a result, the average undervaluation of our portfolio is now over 100% compared to our price targets.

Aescap Life Sciences Quarterly Update Q3 2021